drugset / Trial / NCT01652339

Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects

NCT01652339

Phase 1 Completed 40 enrolled Hanlim Pharm. Co., Ltd.
RandomizedCrossoverOpen-label

Summary

To assess the pharmacokinetic characteristics of Lodivixx tab.5/160mg in healthy male subjects * PK parameter evaluation * Safety profile evaluation

Timeline

Start
2012-07
Primary completion
2012-08
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 10 mg
Subject S-amlodipine Unknown 5 mg
Comparator Valsartan Small molecule 160 mg

Indications

No indication recorded.